Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:12:18 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:IPHA - INNATE PHARMA SPON ADS EACH REP 1 ORD SHS - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
IPHA - Q0.11.61·2.170.11.92+0.14968.516.8251031.89  1.98  1.893.5107  1.2915:57:44Jul 0415 min RT 2¢

Recent Trades - Last 10 of 103
Time ETExPriceChangeVolume
15:57:44Q1.920.149640
15:57:44Q1.920.1496310
15:23:55Q1.900.129622
15:18:55Q1.9350.1646151
15:12:47Q1.9050.13461
15:12:27Q1.890.119658
15:06:27Q1.91250.142125
14:39:09Q1.950.179648
14:38:50Q1.890.119649
14:16:36Q1.97550.2051115

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-04 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of July 3, 2025
2025-06-17 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
2025-06-13 01:00U:IPHANews ReleaseInnate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
2025-05-27 01:00U:IPHANews ReleaseInnate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
2025-05-23 01:00U:IPHANews ReleaseInnate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
2025-05-23 01:00U:IPHANews ReleaseOutcome of Innate Pharma's 2025 Annual General Meeting
2025-05-19 01:00U:IPHANews ReleaseInnate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
2025-05-15 01:00U:IPHANews ReleaseInnate Pharma Highlights ANKET(TM) Abstracts Selected for the EHA 2025 Congress
2025-05-13 01:00U:IPHANews ReleaseInnate Pharma Reports First Quarter 2025 Business Update and Financial Results
2025-05-12 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of May 5, 2025
2025-05-06 01:00U:IPHANews ReleaseInnate Pharma announces conference call and webcast for Q1 2025 business update
2025-04-30 11:30U:IPHANews ReleaseInnate Pharma Files Its 2024 Universal Registration Document (Document d'enregistrement universel) and 2024 Annual Report on Form 20-F
2025-04-29 15:00U:IPHANews ReleaseInnate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
2025-04-28 01:00U:IPHANews ReleaseNumber of Shares and Voting Rights of Innate Pharma as of April 25, 2025
2025-04-24 01:35U:IPHANews ReleaseInnate Pharma Announces euros15M Investment by Sanofi
2025-04-23 01:00U:IPHANews ReleaseInnate Pharma Regains Its Rights on CD123 Targeting ANKET(TM) and Announces Sanofi's Intention to Make a Strategic Investment in the Company
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
2025-04-16 01:00U:IPHANews ReleaseInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
2025-04-03 01:00U:IPHANews ReleaseInnate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
2025-03-27 02:00U:IPHANews ReleaseInnate Pharma Reports Full Year 2024 Financial Results and Business Update